| pubmed-article:7527690 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7527690 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:7527690 | lifeskim:mentions | umls-concept:C0042769 | lld:lifeskim |
| pubmed-article:7527690 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7527690 | lifeskim:mentions | umls-concept:C0149615 | lld:lifeskim |
| pubmed-article:7527690 | lifeskim:mentions | umls-concept:C0039730 | lld:lifeskim |
| pubmed-article:7527690 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7527690 | pubmed:dateCreated | 1995-1-19 | lld:pubmed |
| pubmed-article:7527690 | pubmed:abstractText | Ninety-eight patients with homozygous-beta thalassemia who had undergone allogeneic bone marrow transplantation (BMT) between May 1990 and March 1992 were tested for hepatitis C antibodies (anti-HCV) before and after BMT. Anti-HCV positivity was detected in 50 of the 98 patients (51%) before BMT. Seroconversion was demonstrated in seven of the 40 evaluable seronegative patients. In four cases it was probably due to the different sensitivity of first and second generation ELISA. Of the 46 evaluable seropositive patients 4 had transient and 5 persistent negativity for HCV antibodies after BMT. The high prevalence of anti-HCV positivity in thalassemic patients is related to the continuous requirement for blood transfusions. We found a strong correlation between biochemical and histological evidence of liver damage and anti-HCV positive status in multi-transfused patients. In our experience HCV hepatitis does not influence the outcome of BMT. | lld:pubmed |
| pubmed-article:7527690 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7527690 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7527690 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7527690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7527690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7527690 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7527690 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7527690 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:7527690 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:AmadeoMM | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:LucarelliGG | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:PolchiPP | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:ErenNN | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:BaroncianiDD | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:GalimbertiMM | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:GiardiniCC | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:AngelucciEE | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:PaolucciSS | lld:pubmed |
| pubmed-article:7527690 | pubmed:author | pubmed-author:BattistiniLL | lld:pubmed |
| pubmed-article:7527690 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7527690 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:7527690 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7527690 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7527690 | pubmed:pagination | 369-72 | lld:pubmed |
| pubmed-article:7527690 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:meshHeading | pubmed-meshheading:7527690-... | lld:pubmed |
| pubmed-article:7527690 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7527690 | pubmed:articleTitle | Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. | lld:pubmed |
| pubmed-article:7527690 | pubmed:affiliation | Divisione Ematologica e Centro Trapianto Midollo Osseo di Muraglia, Ospedale di Pesaro, Italy. | lld:pubmed |
| pubmed-article:7527690 | pubmed:publicationType | Journal Article | lld:pubmed |
